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ABSTRACT
Objective Annual gains in life expectancy in Scotland 
were slower in recent years than in the previous two 
decades. This analysis investigates how deaths in different 
age groups and from different causes have contributed to 
annual average change in life expectancy across two time 
periods: 2000–2002 to 2012–2014 and 2012–2014 to 
2015–2017.
Setting Scotland.
Methods Life expectancy at birth was calculated from 
death and population counts, disaggregated by 5 year age 
group and by underlying cause of death. Arriaga’s method 
of life expectancy decomposition was applied to produce 
estimates of the contribution of different age groups and 
underlying causes to changes in life expectancy at birth for 
the two periods.
Results Annualised gains in life expectancy between 
2012–2014 and 2015–2017 were markedly smaller than 
in the earlier period. Almost all age groups saw worsening 
mortality trends, which deteriorated for most cause of 
death groups between 2012–2014 and 2015–2017. 
In particular, the previously observed substantial life 
expectancy gains due to reductions in mortality from 
circulatory causes, which most benefited those aged 
55–84 years, more than halved. Mortality rates for those 
aged 30–54 years and 90+ years worsened, due in large 
part to increases in drug- related deaths, and dementia and 
Alzheimer’s disease, respectively.
Conclusion Future research should seek to explain the 
changes in mortality trends for all age groups and causes. 
More investigation is required to establish to what extent 
shortcomings in the social security system and public 
services may be contributing to the adverse trends and 
preventing mitigation of the impact of other contributing 
factors, such as influenza outbreaks.
INTRODUCTION
Life expectancy improvement rates in Scot-
land have been slower since 2012–2014 than 
in previous decades, the inequalities gradient 
across the deprivation scale has steepened, 
and age- standardised mortality rates have 
increased for those living in the most deprived 
areas, leading to widening health inequal-
ities.1 2 This comes against a background of 
consistently lower life expectancy in Scotland 
compared with the rest of Western Europe 
since the 1980s, and consistently worse socio-
economic inequalities in mortality.3
A similar slow- down since around 2012 in 
the long- term trend of life expectancy has 
been observed across many high- income 
countries.2 4 5 Among 20 high- income coun-
tries, only the USA had a slower improvement 
in life expectancy than the UK in the most 
recent 6 years compared with the previous 
6 years.6 Continued improvements have been 
Strengths and limitations of this study
 ► This is the first paper to describe the contribution of 
specific age groups and causes of death to recent 
changes in life expectancy in Scotland.
 ► It uses a high- quality dataset of deaths in which 
very few death registrations are missing and where 
less than 10% of deaths are coded using ill- defined 
causes.
 ► The results are limited to describing trends rath-
er than explaining causal social and biological 
processes.
 ► The analysis does not identify the mechanism 
through which a given cause of death exerts an ef-
fect on life expectancy.
 ► The analysis of cause of death within age group re-
quired broad groupings of causes of death, which is 
likely to conflate diverse causal mechanisms.
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seen in some of the countries with the highest life expec-
tancies, and among people living in more affluent areas, 
both of which undermine suggestions that the recent 
trends are due to a ‘natural ceiling’ being reached.2 5
Other explanations for the recent trends have included: 
that the UK, along with much of the rest of Western Europe, 
has experienced exceptionally high winter mortality7–9; 
that an increase in ‘deaths of despair’—those from 
alcohol, drugs and suicides—have offset broader health 
improvements10; that funding for health and social care 
services has not kept up with demand11 12; and, relatedly, 
that austerity policies have impacted on health through 
mechanisms such as reduced social security payments 
and underemployment.13 14 Such explanations are likely 
neither mutually exclusive nor exhaustive, and some 
(such as additional winter deaths and slowing improve-
ments in ischaemic heart disease (IHD) mortality) may 
plausibly result from other causes, such as increased pres-
sure on healthcare services and associated unmet need.15
Many of the above explanations differ about how 
mortality changes for specific age groups, and causes, 
have contributed to the overall slow- down in life expec-
tancy growth. This includes increases in several coun-
tries in mortality from dementia/Alzheimer’s disease, 
drug- related deaths and suicide and marked slow- downs 
in the previous rapid improvements in cardiovascular 
mortality.9 10
We aimed to explore the reasons for these recent 
changes by describing the contribution of specific age 
groups and causes of death to the slow- down in life expec-
tancy growth in Scotland in two successive time periods 
(2000–2002 to 2012–2014 and 2012–2014 to 2015–2017).
METHODS
We used repeat cross- sectional data to undertake compar-
ative decomposition analyses of life expectancy over time. 
The data used includes all deaths which occurred in Scot-
land from 2000 to 2017 (inclusive) as held by National 
Records of Scotland.
Period life expectancy at birth was calculated from 
abridged life tables available from National Records of 
Scotland for males and females separately, using 3 years 
combined data to allow robust breakdowns by cause of 
death and age group.16 For the age group decompo-
sition, death counts and population data in 5 years age 
groups were used, separating <1 year from 1 to 4 years 
and using 90+ years as the oldest age category. For the 
cause of death decomposition, International Statistical 
Classification of Diseases and Related Health Problems 
10th Revision (ICD) categories were grouped into 26 
categories. These groupings are exclusive and exhaus-
tive, and were developed on the basis that: at least the 
five leading causes of death should be separate catego-
ries; proposed and plausible contributory causes to life 
expectancy changes should be independent categories; 
and that the residual group should overall make a small 
contribution to life expectancy changes. The leading 
causes of death categorisation used by the Office for 
National Statistics was employed as the basis to deter-
mine groupings where appropriate.17 Due to the overlaps 
between drug- related deaths and other causes (mental 
and behavioural excluding dementia, suicides, accidents 
and other external), for the purposes of this analysis 
these four causes exclude drug- related deaths (online 
supplemental file 1).
We calculated the changes in life expectancy between 
3- year rolling periods for males and females for the whole 
time series from 1980 before focusing on two time periods 
from 2000 onwards. (The 10th revision of ICD was imple-
mented in 2000 in Scotland and data prior to this period 
is not consistent across the cause of death categories 
examined.) Life expectancy growth between 2000–2002 
and 2012–2014 and between 2012–2014 and 2015–2017 
was decomposed into age and cause components using 
Arriaga’s method with the aid of syntax developed by 
Auger et al.18 19 The break between the two periods was 
selected on the basis of the previously identified change 
in mortality trend which showed that the best estimate of 
when mortality rates changed to a slower rate of improve-
ment was the year to 2012 quarter 4 for men and the year 
to 2014 quarter 2 for women.2 As life expectancy data is 
based on 3- year rolling periods, 2012–2014 was chosen to 
most accurately reflect this breakpoint. Life expectancy 
change and decomposition results are presented as annu-
alised change in life expectancy (in weeks) to account for 
the different length of the two time periods. For the anal-
ysis of cause of death within age group, the age and cause 
of death categories were aggregated into five mutually 
exclusive age groups, and eight mutually exclusive cause- 
of- death groupings (40 age- cause groupings). A more 
detailed disaggregation (20 age groups and 26 cause- of- 
death groups) is presented in online supplemental files 
2 and 3.
Patient and public involvement
This research was done without direct patient or public 
involvement.
RESULTS
Rate of improvement in life expectancy
Life expectancy in Scotland had increased steadily until 
around 2012, but improvements have since stalled and 
life expectancy has decreased in recent years. Although 
the rate of improvement has fluctuated over time, it has 
rarely been as low as in the last few years, and any slower 
periods have not been sustained (figure 1).
Decomposition of life expectancy changes by age and sex
In the earlier period (2000–2002 to 2012–2014) the annu-
alised increase in male life expectancy was 16.3 weeks/
year. However, during the later period (2012–2014 to 
2015–2017) male life expectancy fell by an average of 
1.1 weeks/year. During the earlier period, all age groups 
contributed to increases in life expectancy (figure 2) 
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though the greatest contribution (61% of the increase) 
came from the 55–79 year age group. During the later 
period, males aged 40–54 years and 90+ years made 
substantial negative contributions to overall changes in 
life expectancy. Although still contributing positively 
to life expectancy growth in the later period, mortality 
improvement among male aged 55–84 years old declined 
markedly and contributed considerably to the slowing 
of life expectancy growth. There was a notable reduc-
tion in the rate of improvement for males aged 15–34 
years, although the smaller number of deaths at these 
ages meant that this made a smaller contribution to the 
overall change in life expectancy. There were also small 
but noticeable declines in the rate of improvement for 
infants and children aged 1–4 years.
Patterns across age groups were similar for females, 
although both the rates of improvement and the scale of 
change were smaller than for males (figure 2). During the 
earlier period female life expectancy grew by 10.0 weeks/
year, with mortality improvements in all age groups. The 
largest contributions to the increase (64%) came from 
the 60 to 84 years age group. During the later period, the 
annualised improvement in life expectancy declined to 
less than 0.1 weeks/year. For those aged 30–49 years and 
85+ years, mortality rates worsened. Mortality improve-
ments among those aged 60–84 years were very much 
reduced compared with the earlier period. There was also 
slowing in improvements for infants, children aged 1–4 
years and 10–14 years old.
Decomposition by detailed cause of death
For males, the single largest cause of the slow- down in 
life expectancy growth was slower improvements in IHD 
mortality (figure 3). In the earlier period, reductions in 
IHD mortality added 5.8 weeks/year to male life expec-
tancy; in the later period they added only 2.2 weeks per 
year. Drug- related deaths made the second biggest contri-
bution for males, changing from a small negative impact 
(−0.4 weeks/year) in the earlier period to a much larger 
negative impact (−2.4 weeks/year) afterwards. Other 
circulatory diseases, cerebrovascular disease, dementia 
and Alzheimer’s disease also made substantial contribu-
tions to the slow- down. Only two causes, ‘other respira-
tory’ and genitourinary, contributed more to male life 
expectancy growth after 2012–2014 than before.
For females, the same broad causes had the largest 
impact on life expectancy growth, although again the 
scale of change was smaller than for males. The single 
largest cause of the slow- down in life expectancy growth 
was IHD mortality. As in males, drug- related deaths had 
the second biggest impact on life expectancy, changing 
from a small negative impact in the earlier period to a 
much larger negative impact in the later one. Improve-
ments in mortality from other circulatory causes reversed 
in the later time period. For cerebrovascular disease, 
there was a marked decline in the rate of improvement 
between the two time periods. Dementia and Alzheimer’s 
disease mortality worsened from the earlier period. For 
some causes female mortality improved after 2012–2014, 
making a positive contribution to life expectancy growth; 
these included lung cancer, other respiratory causes, 
other cancers, genitourinary, ill- defined causes and breast 
cancer.
Decomposition by age and broad causes of death
The contributions of different causes of death to life 
expectancy trends varied across age groups but were 
generally similar between males and females. For those 
aged <35 years, improvements in mortality from external 
causes made the greatest single contribution to the posi-
tive trend in the earlier period (2000–2002 to 2012–2014). 
In the later period (2012–2014 to 2015–2017) this fell to 
Figure 1 Life expectancy and annual change in life expectancy, 1980–1982 to 2015–2017, by sex, Scotland.
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0.3 weeks/year for males and disappeared for females. 
Mortality rates for drug- related deaths and cancers 
increased slightly in the later time period for those aged 
<35 years (figure 4).
For those aged 35–54 years, the overall negative 
contribution to life expectancy changes was due both 
to substantial reductions in the rate of improvement for 
some causes of death (including circulatory causes) and 
absolute increases in mortality for others (such as drug- 
related deaths, cancers and other causes; figures 4 and 5).
Although the overall contribution to life expectancy 
of those aged 55–74 years remained positive in the later 
period, the dramatic decline in the positive contribution 
of this age group is important in explaining overall 
trends (figure 2). Much of this decline was explained by 
the much slower improvement in deaths from circula-
tory causes in the later compared with the earlier period. 
Improvements in cancer mortality slowed among males 
but increased markedly among females. For both males 
and females, deaths due to dementia, drugs and other 
causes all made negative contributions in the later time 
period to life expectancy growth (figures 4 and 5).
The contributions of broad causes of death to trends in 
life expectancy among those aged 75–89 years was similar 
to that of those aged 55–74 years, but the negative contri-
bution of dementia and Alzheimer’s disease increased in 
Figure 2 Decomposition of changes in life expectancy between 2002–2002 and 2012–2014, and from 2012–2014 to 2015–
2017, by sex, Scotland.
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the later period. Improvements in mortality from circu-
latory causes fell substantially. Positive trends in cancer 
mortality improved further for both males and females 
between the earlier and later periods (figures 4 and 5).
Among the oldest age group (90+ years), the small 
overall contribution to life expectancy growth changed 
from positive to negative between the earlier and later 
time periods (figure 2). This was due to worsening 
mortality due to dementia as well as a slowing in the rate 
of improvement due to circulatory causes (figures 4 and 
5).
More detailed age groups and causes of death are 
presented in online supplemental files 2 and 3. These 
show that mortality in the first year of life from causes of 
death originating in the perinatal period has improved at 
a slower rate since 2012–2014 for males and has worsened 
slightly for females (although given the relatively small 
numbers and the fact that this has not occurred for both 
sexes, this finding should be treated with caution). The 
detailed findings also indicate that the increasingly nega-
tive contribution of drug- related deaths to life expectancy 
trends is mainly concentrated among 35–44 years old for 
females and 40–49 years old for males. The slow- down of 
improvements in IHD mortality is mainly concentrated 
in male aged 60–69 years and female aged 65–74 years; 
the negative contribution of suicides is concentrated in 
Figure 3 Decomposition of the contribution of specific causes of death to changes in life expectancy between 2000–2002 and 
2012–2014 and between 2012–2014 and 2015–2017, by sex, Scotland.
*Excluding causes that are included under drug- related deaths. IHD, ischaemic heart disease.
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males aged 25–29 years old, and the rising contribution of 




Life expectancy in Scotland steadily improved from 
the early 1980s until 2012–2014, after which the rate of 
improvement slowed, followed by declines in life expec-
tancy between 2014–2016 and 2015–2017. Between 2000–
2002 and 2012–2014, annualised increases in male and 
female life expectancy were 16.3 and 10.0 weeks/year, 
respectively, but this changed to a decline of 1.1 weeks/
year for males and to a very small increase of less than 
0.1 weeks/year for females between 2012–2014 and 2015–
2017. In the earlier period, most of the increases in life 
expectancy were due to falling mortality among those 
aged 55–84 years, although mortality rates declined for all 
age groups. In the later period, declines in mortality were 
slower for all age groups, particularly those aged 55–84 
years. Mortality increased for males aged 30–54 years, 
females aged 35–49 years and both males and females 
aged 90+ years.
Almost all causes of death demonstrated a change in 
trend in the recent period. Although mortality due to IHD 
and cerebrovascular disease continued to decline in the 
later period, life expectancy gains due to these conditions 
were less than half of those in the earlier period. This 
affected all age groups, but was particularly important in 
explaining the slowing in improvement for those aged 
55–74 years, and to a lesser extent those aged 35–54 years. 
Mortality from drug- related causes and from dementia 
and Alzheimer’s disease, which were already making 
negative contributions to life expectancy in the earlier 
period, made larger negative contributions after 2012–
2014. The previous favourable trends in mortality from 
other circulatory causes reversed. The increase in drug- 
related deaths was particularly important in explaining 
increasing mortality among those aged 35–54 years, while 
increases in dementia and Alzheimer’s disease mortality 
substantially explained trends among those aged 90+ 
years.
Strengths and limitations
The key strengths of this analysis are the use of a complete 
mortality dataset for the whole population which reduces 
the risk of bias from missing data or selection biases. 
Less than 10% of deaths in Scotland are coded using 
ill- defined causes. We also use standard decomposition 
analysis (Arriaga) methods that are thereby comparable 
to estimates produced for other populations. The analysis 
is limited to the use of cause of death codes which do not 
illuminate the overall social causation and mechanisms 
leading to mortality—this is the subject of other work. We 
also had to use broad grouping of death codes within age 
groups to improve the precision of our estimates which is 
likely to conflate diverse causal mechanisms.
How this compares with existing research
The stalling in life expectancy trends in Scotland is of 
a similar magnitude to the rest of the UK and USA, but 
greater than in some other parts of Europe.2 4 5 Much 
Figure 4 Decomposition of changes in life expectancy by 
grouped age and cause of death, 2000–2002 to 2012–2014 
and 2012–2014 to 2015–2017, by sex, Scotland.
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of the initial research describing recent slowing in life 
expectancy gains has focused on the role of influenza 
and mortality among the oldest age groups.9 20 Although 
we report increases in deaths due to influenza and respi-
ratory causes, and rising mortality among those aged 
90+ years, these results show that the contribution they 
make to explaining the overall slowing in life expectancy 
growth in Scotland is small. This is consistent with other 
studies in England and Wales and the USA which report 
that slowing improvements for IHD and cerebrovascular 
disease and increases in mortality for other circulatory 
causes among 55–84 years old and drug- related deaths 
for adults aged 35–49 years, all make substantial contri-
butions to the overall trends.21–25 The slightly slower rate 
of improvement in the most recent period for women 
compared with men indicates that the long- term closing 
of the sex gap seems to be continuing.
There is evidence that the increase in drug- related 
deaths in Scotland is due in part to a cohort effect among 
males who were young adults during the 1980s.26 Some 
recent trends may, therefore, be attributable to historical 
exposures to political and social change at that time and 
before, whereby risk of mortality accumulates over time 
within that cohort.3 26
The reasons for slowing improvements in cardiovas-
cular disease mortality is not clear. Possible explanations 
might include slowing of progress in reducing exposure 
to tobacco, increases in the prevalence of obesity, changes 
in psychosocial risk factors related to economic insecurity 
or deterioration in access to, or the quality of, health and 
social care services.27 This should be the focus of further 
specific work to understand the timing and reasons for 
the stalling.28
The increase in mortality from dementia and Alzhei-
mer’s disease has been attributed to a number of factors, 
including: people living longer and surviving other 
illnesses29; increased awareness of dementia, making 
it more likely to be diagnosed and recorded9 25 and 
National Health Service policies encouraging dementia 
diagnosis.25 Changes in death certification practices 
have also been cited as one of the reasons for increase in 
deaths from dementia and Alzheimer’s disease,6 although 
it should be noted that these changes did not occur in 
Scotland until 2017 so will have had a limited impact on 
these results.
Implications
Several hypotheses have been proposed to explain recent 
life expectancy trends in Scotland and other high- income 
countries.15 Further research should include work to 
understand the mechanisms and processes underlying the 
changes at different life- course stages: the considerable 
rise in drug- related deaths among working- age adults; 
the substantial slow- down in improvements for IHD, cere-
brovascular disease and other circulatory causes; and the 
rise in mortality from dementia and Alzheimer’s disease 
among those aged 90+ years.
The recent change in life expectancy trends represents 
a very substantial mortality impact which needs to be 
reflected in the level of priority given to understanding 
this further. Mortality has worsened (through slowing 
improvements or mortality increases) across many age 
groups and causes, so it is unlikely that any single factor 
provides sufficient explanation. The extent to which there 
is a common underlying cause or exposure affecting each 
of these age groups should be prioritised for further 
investigation.
Figure 5 Decomposition of change in life expectancy growth pre and post 2012–2014 by grouped age and cause of death, by 
sex, Scotland.
Values in cells indicate the difference in contribution to life expectancy change between the two periods, in weeks per year. Positive 
contributions are shaded blue and outlined with boxes. Negative contributions are shaded red and have no box outline.
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Supplementary file 1: Categorisation of Causes of Death 
 
# Detailed Category (26) ICD-10 Grouped 
Category (8) 
1 Infectious diseases A00-B99 Other 
2 Lung cancer C33-C34 Cancers 
3 Prostate cancer C61 Cancers 
4 Breast cancer C50 Cancers 
5 Bowel cancer C18-C21 Cancers 
6 Other cancers All other C codes Cancers 
7 Diabetes E10-E14 Other 
8 Dementia and Alzheimer's F01, F03, G30 Dementia and 
Alzheimer's 
9 Mental  and behavioural disorders 
excluding dementia * 
All other F codes Other 
1
0 
Nervous system diseases excluding 
Alzheimer’s 
All other G codes Other 
1
1 
Ischaemic heart disease I20-I25 Circulatory 
1
2 
Cerebrovascular I60-I69 Circulatory 
1
3 
Other circulatory All other I codes Circulatory 
1
4 
Influenza and pneumonia J09-J18 Respiratory 
1
5 
Chronic lower respiratory diseases J40-J47 Respiratory 
1
6 
Other respiratory All other J codes Respiratory 
1
7 





Cirrhosis and other diseases of the liver K70-K76 Other 
1
9 
Genitourinary N00-N99 Other 
2
0 
Perinatal conditions P00-P96 Other 
2
1 
Ill-defined R00-R99 Other 
2
2 
Suicide and injury/poisoning of 






Accidents * V01-X59, Y85-Y86 External 
2
4 
Other external * All other X&Y codes External 
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2
5 
Residual All D 









Drug-related F11-F15, F19,  Plus 
X40-X44, X60-X64, 
X85, Y10-Y14 where a 
controlled drug was 
present in the body. 
Drug-related 
* excluding deaths which are also classified as drug-related.  
 
As the drug-related codes overlap with mental and behavioural causes (exc. dementia) and external 
causes (suicides, accidents and other external), where a death would appear in both categories, we 
included it in the drug-related category only, and therefore the other 4 categories exclude drug-
related deaths.  This was done for two reasons: firstly, the interest in the impact of recent drug -
related death trends; and secondly, because of ICD coding changes in 20111 there is a discontinuity 
in the figures for external causes and mental and behavioural causes. This change caused deaths 
which would previously have been coded as mental and behavioural causes to be coded as external 
causes.  As this change occurred at a key point in the time period we are analysing, it would give 
misleading results on the relative impact of these causes on life expectancy growth. The coding 
change did not affect the figures for drug-related deaths, so by selecting these as a separate 
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